Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pfizer Inc. (PFE) is preparing a Phase 1 study called “A PHASE 1, OPEN LABEL, SINGLE DOSE, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF TWO FORMULATIONS OF A CGRP RECEPTOR ANTAGONIST IN HEALTHY ADULT PARTICIPANTS.” The goal is to compare blood levels of two oral migraine formulations and confirm that a new tablet matches the approved version, which could support a more flexible product line.
The trial tests two oral drugs: an ODT2 test formulation and an existing orally disintegrating tablet used as the reference. Both contain a CGRP receptor blocker aimed at migraine, and the study checks if the new tablet dissolves and absorbs in the body in the same way as the current approved option.
This is an interventional Phase 1 study with randomized allocation and a crossover model, meaning the same healthy adults will receive both formulations in different sequences. The trial is open label with no blinding, and the primary purpose is to demonstrate similar drug exposure rather than to test clinical benefit or safety in patients.
The study was first submitted on 12 May 2026 and had its latest update on 19 May 2026, signaling that planning is active but recruitment has not yet begun. Primary and final completion dates are not yet posted, so investors should expect data to emerge some time after first dosing, typical for short, single‑dose bioequivalence work.
For investors, this update suggests Pfizer is optimizing an existing migraine asset rather than betting on a brand‑new drug, which can support lifecycle management and modestly extend revenue. It also keeps PFE engaged in the competitive CGRP migraine space, where players like AbbVie and Eli Lilly are active, but near‑term stock impact is likely limited given the early stage and low risk of the study.
The study remains in the startup phase with ongoing updates, and investors can track further details and timing on the ClinicalTrials portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.